<DOC>
	<DOCNO>NCT00160199</DOCNO>
	<brief_summary>To evaluate efficacy safety 300 mg 400 mg dos PROMETRIUM® capsule woman reproductive age secondary amenorrhea</brief_summary>
	<brief_title>Safety Efficacy PROMETRIUM® Capsules Induction Secretory Conversion</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Amenorrhea</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Women secondary amenorrhea Normal serum Dehydroepiandrosterone ( DHEA ) , prolactin , testosterone , Thyroid Stimulating Hormone ( TSH ) thyroxine Primary amenorrhea Other medical condition result amenorrhea ( e.g . Asherman 's syndrome ) Peanut allergy Allergy progestational steroid</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>To collect additional data 300 400 mg dos PROMETRIUM woman secondary amenorrhea</keyword>
</DOC>